Company: BNRG
Filing Date: 2025-11-25
Form Type: 424B3
Source: 0001213900-25-114795
Chunk: 9

Company: Brenmiller Energy Ltd.
Filing Date: 2025-11-25
Form: 424B3
Chunk 9
---
 anti-dilution provision which, subject to limited exceptions,
would reduce the exercise price of the warrants or the conversion price of the preferred shares (and increase the number of shares issuable)
in the event that we in the future issue ordinary shares, or securities convertible into or exercisable to purchase ordinary shares,
including any securities issued to Alpha in connection with any subsequent financing in connection to the July 2025 Securities Purchase Agreement,
at a price per share lower than the applicable exercise price or conversion price then in effect.

You may experience future dilution as a result of future equity offerings and other issuances of our securities.

In order to raise additional
capital, we may in the future offer additional Ordinary Shares or other securities convertible into or exchangeable for our Ordinary
Shares prices that may not be the same as the price per share paid by the investors in this offering. We may not be able to sell shares
or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by the investors
in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders.
The price per share at which we sell additional Ordinary Shares or securities convertible into Ordinary Shares in future transactions
may be higher or lower than the price per share paid to the selling shareholders. Our shareholders will incur dilution upon exercise
of any outstanding share options, warrants or other convertible securities or upon the issuance of Ordinary Shares under our share incentive
programs.

Any additional capital raised
through the sale of equity or equity-backed securities may dilute our shareholders’ ownership percentages and could also result
in a decrease in the market value of our equity securities.

The terms of any securities
issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights
and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities
then outstanding.

In addition, we may incur
substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law
compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection
with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.

As a result of the shutdown of the U.S. federal government, we have determined to rely on Section 8(a) of the Securities Act to cause